High-Dose IL-2 in Metastatic Kidney Cancer: Outcomes by Risk Groups
Posted: Wednesday, May 15, 2019
Although prognostic scoring systems have not been extensively used to assess mortality risk among patients with metastatic renal cell carcinoma receiving high-dose interleukin-2 (IL-2), a new study supports the survival benefits of this treatment, particularly in favorable-risk patients. Mayer Fishman, MD, of the Moffitt Cancer Center, Tampa, Florida, published their findings in the Journal for ImmunoTherapy of Cancer.
The authors analyzed survival outcomes in 810 patients with metastatic renal cell carcinoma using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk criteria. Approximately 25% of patients were analyzed retrospectively, and 75% were analyzed prospectively in the PROCLAIMSM registry database. The results focus on the 356 patients who received high-dose interleukin-2 alone.
Patients in the favorable- and intermediate-risk groups treated with high-dose IL-2 achieved longer overall survival and 2-year overall survival than patients in the poo- risk group. The median overall survival was 65.4 months and the 2-year overall survival rate was 73.4% among patients in the favorable-risk category. Overall survival in the intermediate- and poor-risk groups was 57.6 months and 14 months, respectively. In the intermediate- and poor-risk categories, the 2-year overall survival rates were 63.7% and 39.8%, respectively.
“These data continue to support a recommendation for high-dose interleukin-2 for patients with [metastatic renal cell carcinoma] who meet eligibility criteria,” the authors concluded. “Data supporting [the] feasibility of concurrent administration of IL-2 with [checkpoint inhibitors] is accumulating, potentially enhancing response rates.”
Disclosure: The study authors’ disclosure information may be found at jitc.biomedcentral.com.